# A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

> **NCT06329791** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Azura Ophthalmics** · enrollment: 500 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** AZR-MD-001
- **OTHER:** Vehicle

## Key facts

- **NCT ID:** NCT06329791
- **Lead sponsor:** Azura Ophthalmics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-28
- **Primary completion:** 2024-12
- **Final completion:** 2025-11
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329791, "A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06329791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*